HLA-C and neoplasm: The MHC class I (HLA-A2) could be removed on donor-derived CAR-T by the same methods to prevent rejection, this strategy inhibits donor CAR-T cell recognition by host TCRαβ via HLA class I. These HLA-A2 negative CAR-T cells were protected from CTL attack and survived in culture with target tumor cells for more than 50 days [134], and MHC absence can incite NK cells’ response to allogeneic T cells.